The use of inhaled combined therapy in the treatment of asthma and chronic obstructive pulmonary disease Review article
Article Sidebar
Published:
Sep 30, 2020
Keywords:
asthma, COPD, combination therapy, inhalation therapy, compliance
Main Article Content
Abstract
Clinical study results showed that combined therapy – inhaled glucocorticosteroid plus long-acting β2-agonists – allows for better control of asthma and chronic obstructive pulmonary disease, reducing the number of exacerbations. There are strong scientific evidence for the use of both drugs in one inhaler, because they exhibit complementary and synergy of clinical activity at the molecular level.
Article Details
How to Cite
Górska , K., & Korczyński , P. (2020). The use of inhaled combined therapy in the treatment of asthma and chronic obstructive pulmonary disease. Medycyna Faktow (J EBM), 13(3(48), 358-365. https://doi.org/10.24292/01.MF.0320.11
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2020.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2020.
3. Hagedorn C, Kässner F, Banik N et al. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD. Respir Med. 2013; 107: 542-9.
4. Laforest L, Denis F, Van Ganse E et al. Correlates of adherence to respiratory drugs in COPD patients. Prim Care Respir J. 2010; 19: 148-54.
5. Weinberg EG, Naya I. Treatment preferences of adolescent patients with asthma. Pediatr Allergy Immunol. 2000; 11: 49-55.
6. Li H-T, Zhang T-T, Zhou H et al. Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma. Respiration. 2007; 74: 33-43.
7. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004; 170: 836-44.
8. Toy EL, Beaulieu NU, McHale JM et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011; 105: 435-41.
9. Coutts JA, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child. 1992; 67: 332-3.
10. Winnicki M, Basiński K, Szyndler A et al. Jak poprawić stopień przestrzegania zaleceń terapeutycznych i jakość współpracy lekarz–pacjent. Choroby Serca i Naczyń. 2016; 13: 194-202.
11. Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am. 2005; 25: 107-30.
12. Jankowska-Polańska B, Uchmanowicz I. Stosowanie się do zaleceń terapeutycznych w niewydolności serca. Choroby Serca i Naczyń. 2016; 13: 227-34.
13. Ágh T, Inotai A, Mészáros Á. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 2011; 82: 328-34.
14. Shapiro G, Lumry W, Wolfe J et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med. 2000; 161: 527-34.
15. Kavuru M, Melamed J, Gross G et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2000; 105: 1108-16.
16. Nelson HS, Busse WW, Kerwin E et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol. 2000; 106: 1088-95.
17. Pearlman DS, Stricker W, Weinstein S et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol. 1999; 82: 257-65.
18. Aubier M, Pieters WR, Schlösser NJ et al. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med. 1999; 93: 876-84.
19. O’Connor RD, Rosenzweig JRC, Stanford RH et al. Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens. Ann Allergy Asthma Immunol. 2005; 95: 535-40.
20. Chan J, Hui RL, Spence MM. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids. J Manag Care Pharm. 2007; 13: 21-7.
21. Stoloff SW, Stempel DA, Meyer J et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004; 113: 245-51.
22. Elkout H, McLay JS, Simpson CR et al. A retrospective observational study comparing rescue medication use in children on combined versus separate long-acting beta-agonists and corticosteroids. Arch Dis Child. 2010; 95: 817-21.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2020.
3. Hagedorn C, Kässner F, Banik N et al. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD. Respir Med. 2013; 107: 542-9.
4. Laforest L, Denis F, Van Ganse E et al. Correlates of adherence to respiratory drugs in COPD patients. Prim Care Respir J. 2010; 19: 148-54.
5. Weinberg EG, Naya I. Treatment preferences of adolescent patients with asthma. Pediatr Allergy Immunol. 2000; 11: 49-55.
6. Li H-T, Zhang T-T, Zhou H et al. Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma. Respiration. 2007; 74: 33-43.
7. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004; 170: 836-44.
8. Toy EL, Beaulieu NU, McHale JM et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011; 105: 435-41.
9. Coutts JA, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child. 1992; 67: 332-3.
10. Winnicki M, Basiński K, Szyndler A et al. Jak poprawić stopień przestrzegania zaleceń terapeutycznych i jakość współpracy lekarz–pacjent. Choroby Serca i Naczyń. 2016; 13: 194-202.
11. Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am. 2005; 25: 107-30.
12. Jankowska-Polańska B, Uchmanowicz I. Stosowanie się do zaleceń terapeutycznych w niewydolności serca. Choroby Serca i Naczyń. 2016; 13: 227-34.
13. Ágh T, Inotai A, Mészáros Á. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 2011; 82: 328-34.
14. Shapiro G, Lumry W, Wolfe J et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med. 2000; 161: 527-34.
15. Kavuru M, Melamed J, Gross G et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2000; 105: 1108-16.
16. Nelson HS, Busse WW, Kerwin E et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol. 2000; 106: 1088-95.
17. Pearlman DS, Stricker W, Weinstein S et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol. 1999; 82: 257-65.
18. Aubier M, Pieters WR, Schlösser NJ et al. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med. 1999; 93: 876-84.
19. O’Connor RD, Rosenzweig JRC, Stanford RH et al. Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens. Ann Allergy Asthma Immunol. 2005; 95: 535-40.
20. Chan J, Hui RL, Spence MM. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids. J Manag Care Pharm. 2007; 13: 21-7.
21. Stoloff SW, Stempel DA, Meyer J et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004; 113: 245-51.
22. Elkout H, McLay JS, Simpson CR et al. A retrospective observational study comparing rescue medication use in children on combined versus separate long-acting beta-agonists and corticosteroids. Arch Dis Child. 2010; 95: 817-21.